AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25338926 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG combined with A1C (FPG ≥5.6 mmol/L and/or A1C ≥5.7% [39 mmol/mol])
Number of subjects: 216
Study 25338926 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C combined with FPG
Number of subjects: 216
Study 25340593 — intervention group
Group type: EXPERIMENTAL
Intervention: poly-L-lactic acid
Number of subjects: 15
Study 25340778 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiretroviral therapy (cART) for 8 months
Number of subjects: 9
Study 25340784 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 agonist therapy
Number of subjects: 230
Study 25340784 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c achieved
Number of subjects: 230
Study 25340784 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c change
Number of subjects: 230
Study 25340854 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence or development of new ECG LVH
Number of subjects: 725
Study 25340854 — intervention group
Group type: COMPARATOR
Intervention: Regression or continued absence of ECG LVH
Number of subjects: 725
Study 25341454 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk algorithms developed using competing risks survival analysis.
Number of subjects: 77251
Study 25341454 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to administrative healthcare databases for incident CVD outcomes assessment.
Number of subjects: 77251
Study 25341556 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema-predominant COPD
Number of subjects: 4197
Study 25341556 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-emphysematous COPD
Number of subjects: 4197
Study 25341628 — intervention group
Group type: EXPERIMENTAL
Intervention: New percentile charts for birth weight, length, and head circumference
Number of subjects: 863
Study 25341628 — intervention group
Group type: COMPARATOR
Intervention: Comparison of new birth weight curves with data from Finland
Number of subjects: 863
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell profiles in adipose tissue (specifically CD4 and CD8 T cells)
Number of subjects: 0
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1 frequency in SAT and VAT
Number of subjects: 0
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2 frequency in VAT
Number of subjects: 0
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: Th2 in both depots and peripheral blood
Number of subjects: 0
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: Th1 in SAT
Number of subjects: 0
Study 25341798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue expression of interleukin-10
Number of subjects: 0
Study 25342141 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI-573 (5 mg/kg, 15 mg/kg, 45 mg/kg on Day 1, 8, and 15 of 21-day cycles)
Number of subjects: 10
Study 25343737 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview survey tool about bullying administered to children
Number of subjects: 50
Study 25344223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile imaging (TI)
Number of subjects: 22
Study 25344362 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib and everolimus (daily dosing with both agents)
Number of subjects: 67
Study 25344362 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib and everolimus (daily dosing with trametinib and intermittent everolimus dosing)
Number of subjects: 67
Study 25344427 — intervention group
Group type: EXPERIMENTAL
Intervention: Case review process for eligibility determination
Number of subjects: 697
Study 25344522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization analyses using extended probe panels applied to CD34(+) peripheral blood cells
Number of subjects: 328
Study 25344522 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete International Prognostic Scoring System assessment including cytogenetic data from fluorescence in situ hybridization analyses
Number of subjects: 328
Study 25344522 — intervention group
Group type: COMPARATOR
Intervention: Chromosome banding results from 2902 previously published patients with MDS
Number of subjects: 328
Study 25344536 — intervention group
Group type: EXPERIMENTAL
Intervention: Clostridium OTU overabundance in prediagnosis samples from infants with established NEC
Number of subjects: 369
Study 25344536 — intervention group
Group type: EXPERIMENTAL
Intervention: Klebsiella OTU overabundance in prediagnosis samples from NEC infants not carrying profuse C. perfringens
Number of subjects: 369
Study 25344536 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged continuous positive airway pressure (CPAP) therapy with supplemental oxygen
Number of subjects: 369
Study 25344620 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual world intervention (Second Life)
Number of subjects: 89
Study 25344620 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face intervention
Number of subjects: 89
Study 25345578 — intervention group
Group type: EXPERIMENTAL
Intervention: ROX coupler implantation in ovine aortas for up to 12 months
Number of subjects: 0
Study 25345697 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 103
Study 25345697 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 103
Study 25347448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 433
Study 25347448 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-psychotic therapy (retrospective)
Number of subjects: 433
Study 25348273 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful early percutaneous revascularization in derivation cohort
Number of subjects: 521
Study 25348273 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful early percutaneous revascularization in validation cohort
Number of subjects: 521
Study 25348520 — intervention group
Group type: EXPERIMENTAL
Intervention: Faldaprevir (480 mg)
Number of subjects: 32
Study 25348520 — intervention group
Group type: COMPARATOR
Intervention: Normal renal function (Control)
Number of subjects: 32
Study 25348520 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal impairment (Experimental)
Number of subjects: 32
Study 25348609 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg elemental zinc, oral zinc acetate, twice daily for 14 days)
Number of subjects: 55
Study 25348609 — intervention group
Group type: COMPARATOR
Intervention: Control group (RR homozygotes)
Number of subjects: 55
Study 25349073 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor pathologic variables alone
Number of subjects: 34
Study 25349073 — intervention group
Group type: EXPERIMENTAL
Intervention: tHb combined with tumor pathological variables
Number of subjects: 34
Study 25349073 — intervention group
Group type: EXPERIMENTAL
Intervention: oxyHb combined with tumor variables
Number of subjects: 34
Study 25349073 — intervention group
Group type: EXPERIMENTAL
Intervention: tHb or oxyHb added to tumor pathologic variables
Number of subjects: 34
Study 25349290 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-WBRT (Hippocampal Avoidance Whole-Brain Radiotherapy) to 30 Gy in 10 fractions
Number of subjects: 113
Study 25349290 — intervention group
Group type: COMPARATOR
Intervention: Historical control (WBRT without hippocampal avoidance)
Number of subjects: 113
Study 25349960 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 50 to 54 years without baseline osteoporosis
Number of subjects: 4068
Study 25349960 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 60 to 64 years without baseline osteoporosis
Number of subjects: 4068
Study 25349960 — intervention group
Group type: EXPERIMENTAL
Intervention: All women aged 50 to 64 years with baseline osteoporosis
Number of subjects: 4068
Study 25349960 — intervention group
Group type: COMPARATOR
Intervention: Women aged 50 to 64 years without osteoporosis on their first BMD test
Number of subjects: 4068
Study 25349968 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (oral angiogenesis inhibitor targeting VEGFR/PDGFR/c-Kit)
Number of subjects: 0
Study 25350762 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (iv-tPA), n=62
Number of subjects: 164
Study 25350762 — intervention group
Group type: COMPARATOR
Intervention: No thrombolysis (Control), n=102
Number of subjects: 164
Study 25350762 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (iv-tPA)
Number of subjects: 164
Study 25350980 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated fat dietary counseling
Number of subjects: 395
Study 25350980 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 395
Study 25350980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex (boys vs girls)
Number of subjects: 395
Study 25351198 — intervention group
Group type: EXPERIMENTAL
Intervention: IK-5001 (2 ml of 1% sodium alginate plus 0.3% calcium gluconate) administered by selective injection through the infarct-related coronary artery within 7 days after myocardial infarction
Number of subjects: 27
Study 25352936 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz monotherapy (600 mg single dose and 600 mg/d for 17 days)
Number of subjects: 60
Study 25353072 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention (M6) with a 3-week residential program (D21)
Number of subjects: 42
Study 25353072 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 42
Study 25353277 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group (neonatal hyperbilirubinaemia)
Number of subjects: 167
Study 25353277 — intervention group
Group type: COMPARATOR
Intervention: Unexposed group (age-, sex-, and gestational age-matched)
Number of subjects: 167
Study 25354824 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency abdominal surgery
Number of subjects: 0
Study 25354827 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE) procedure
Number of subjects: 16
Study 25354827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI and contrast-enhanced ultrasound of the prostate
Number of subjects: 16
Study 25354827 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole mount histopathological examination
Number of subjects: 16
Study 25355245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenalidomide at a dose of 25 mg daily on days 1 to 21 of each 28-day cycle
Number of subjects: 39
Study 25355284 — intervention group
Group type: EXPERIMENTAL
Intervention: 160-mg subcutaneous ixekizumab injection at Week 0, 80-mg every 2 weeks through Week 12 and 80-mg every 4 weeks through Week 24
Number of subjects: 91
Study 25355590 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH test for high response prediction
Number of subjects: 487
Study 25355590 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH test for low response prediction
Number of subjects: 487
Study 25355590 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH test with specificity of ∼90% for high response
Number of subjects: 487
Study 25355590 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH test with specificity of ∼90% for low response
Number of subjects: 487
Study 25355590 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ongoing pregnancy rates among groups
Number of subjects: 487
Study 25355590 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH vs. female age and BMI for prediction accuracy
Number of subjects: 487
Study 25355699 — intervention group
Group type: EXPERIMENTAL
Intervention: (124)I-cRGDY-PEG-C dot particles
Number of subjects: 0
Study 25355716 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPARC expression (IRS ≥6)
Number of subjects: 667
Study 25355716 — intervention group
Group type: COMPARATOR
Intervention: Low SPARC expression (IRS <6)
Number of subjects: 667
Study 25355716 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPARC expression in triple-negative tumors
Number of subjects: 667
Study 25355716 — intervention group
Group type: COMPARATOR
Intervention: Low SPARC expression in triple-negative tumors
Number of subjects: 667
Study 25355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal therapy (RCT)
Number of subjects: 708
Study 25355775 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline factors predicting severe postoperative pain
Number of subjects: 708
Study 25355819 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (280 or 560 mg) combined with rituximab (375 mg/m(2)) and bendamustine (90 mg/m(2))
Number of subjects: 48
Study 25355844 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg efavirenz daily
Number of subjects: 53
Study 25355844 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal plasma concentration of efavirenz
Number of subjects: 53
Study 25355844 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal plasma concentration of efavirenz
Number of subjects: 53
Study 25356881 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD exacerbations requiring hospital admission
Number of subjects: 2138
Study 25356881 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior history of exacerbation requiring hospital admission
Number of subjects: 2138
Study 25356881 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for exacerbation
Number of subjects: 2138
Study 25357008 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention via Facebook
Number of subjects: 21
Study 25357008 — intervention group
Group type: COMPARATOR
Intervention: Informational control via Facebook
Number of subjects: 21
Study 25357043 — intervention group
Group type: EXPERIMENTAL
Intervention: AeroForm patient-controlled tissue expanders; 10-cc dose of carbon dioxide gas administered three times daily with a 3-hour lockout until full expansion achieved.
Number of subjects: 33
Study 25357043 — intervention group
Group type: COMPARATOR
Intervention: AeroForm breast tissue expander
Number of subjects: 33
Study 25358735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic structure-function (DSF) model
Number of subjects: 220
Study 25358735 — intervention group
Group type: COMPARATOR
Intervention: Ordinary least squares linear regression (OLSLR)
Number of subjects: 220
Study 25358826 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase type 5 inhibitors (PDE5i)
Number of subjects: 64
Study 25358826 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly use of PDE5i
Number of subjects: 64
Study 25358868 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic abdominal pain (CAP) group
Number of subjects: 59
Study 25358868 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study 25358868 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with poor sleep quality
Number of subjects: 59
Study 25358868 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with CAP
Number of subjects: 59
Study 25358868 — intervention group
Group type: EXPERIMENTAL
Intervention: BDNF genotype interaction
Number of subjects: 59
Study 25358868 — intervention group
Group type: EXPERIMENTAL
Intervention: Down-regulation of specific genes (IGF1, SPATS2L, IGHG1)
Number of subjects: 59
Study 25359291 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and adalimumab treatment
Number of subjects: 39
Study 25359291 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 39
Study 25359291 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab treatment
Number of subjects: 39
Study 25359291 — intervention group
Group type: COMPARATOR
Intervention: Baseline sOX40L levels
Number of subjects: 39
Study 25359291 — intervention group
Group type: COMPARATOR
Intervention: sOX40/sOX40L ratio
Number of subjects: 39
Study 25359432 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele of rs1205 C > T genotype (TT)
Number of subjects: 315
Study 25359432 — intervention group
Group type: EXPERIMENTAL
Intervention: Common H2 haplotype characterized by the T allele of rs1205
Number of subjects: 315
Study 25359432 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs and haplotypes
Number of subjects: 315
Study 25359642 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring (oral hygiene instruction, applying or prescribing fluoride or varnish, or both)
Number of subjects: 1341
Study 25359642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant
Number of subjects: 1341
Study 25359642 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive therapy
Number of subjects: 1341
Study 25359642 — intervention group
Group type: EXPERIMENTAL
Intervention: Young patient age (< 18 years)
Number of subjects: 1341
Study 25359642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesion on a molar
Number of subjects: 1341
Study 25359677 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25359988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and chemotherapy (6 5-day cycles with high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, ifosphamide, corticosteroids, and triple intrathecal therapy; Rituximab given before each cycle and twice as maintenance, total of 8 doses)
Number of subjects: 363
Study 25359988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and chemotherapy
Number of subjects: 363
Study 25359994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine pathway treatment targeting STAT3
Number of subjects: 13
Study 25360300 — intervention group
Group type: EXPERIMENTAL
Intervention: GORD diagnosed based on reflux oesophagitis, pathological oesophageal acid exposure, and/or positive symptom-acid association probability.
Number of subjects: 336
Study 25360300 — intervention group
Group type: COMPARATOR
Intervention: Physician interviews using a prespecified symptom checklist.
Number of subjects: 336
Study 25360300 — intervention group
Group type: COMPARATOR
Intervention: Reflux Disease Questionnaire (RDQ).
Number of subjects: 336
Study 25360888 — intervention group
Group type: EXPERIMENTAL
Intervention: A-allele of the rs12041331 SNP in the PEAR1 gene
Number of subjects: 985
Study 25360888 — intervention group
Group type: COMPARATOR
Intervention: Other SNPs analyzed
Number of subjects: 985
Study 25360888 — intervention group
Group type: COMPARATOR
Intervention: 14 SNPs previously suggested to influence aspirin efficacy
Number of subjects: 985
Study 25361564 — intervention group
Group type: EXPERIMENTAL
Intervention: TAo-TAVI using the Edwards SAPIEN Valve
Number of subjects: 300
Study 25361625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (starting dose 200 mg/day, escalated to a maximum of 1,000 mg/day) combined with TACE
Number of subjects: 56
Study 25361625 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide and TACE
Number of subjects: 56
Study 25361643 — intervention group
Group type: EXPERIMENTAL
Intervention: GDm-health system (smartphone-based blood glucose monitoring)
Number of subjects: 52
Study 25361834 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 796
Study 25361834 — intervention group
Group type: COMPARATOR
Intervention: Non-T2DM group
Number of subjects: 796
Study 25361837 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised DAPT guided by MEA (treatment for HPR to ADP with prasugrel or ticagrelor, clopidogrel reloading)
Number of subjects: 1008
Study 25361837 — intervention group
Group type: COMPARATOR
Intervention: Individualised DAPT guided by MEA
Number of subjects: 1008
Study 25361987 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-Ibritumomab tiuxetan in association with a fludarabine-based reduced-intensity conditioning (RIC) regimen
Number of subjects: 31
Study 25361995 — intervention group
Group type: EXPERIMENTAL
Intervention: Young adults (18-29 years old)
Number of subjects: 2784
Study 25361995 — intervention group
Group type: COMPARATOR
Intervention: Adults (30-59 years old)
Number of subjects: 2784
Study 25361995 — intervention group
Group type: COMPARATOR
Intervention: Elderly patients (at least 60 years old)
Number of subjects: 2784
Study 25361995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors-treated young adults (18-29 years old)
Number of subjects: 2784
Study 25361995 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors-treated adults (30-59 years old)
Number of subjects: 2784
Study 25361995 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors-treated elderly patients (at least 60 years old)
Number of subjects: 2784
Study 25362970 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until progression or unacceptable toxicities
Number of subjects: 34
Study 25363015 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D and 3D ultrasound estimations of uterine volume
Number of subjects: 81
Study 25363015 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D observations of uterine volume
Number of subjects: 81
Study 25363015 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance index (RI) of the uterine artery
Number of subjects: 81
Study 25363015 — intervention group
Group type: EXPERIMENTAL
Intervention: RI of the arcuate artery
Number of subjects: 81
Study 25363015 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine involution
Number of subjects: 81
Study 25363329 — intervention group
Group type: EXPERIMENTAL
Intervention: TB-DM (Type 2 diabetes mellitus with pulmonary tuberculosis)
Number of subjects: 0
Study 25363329 — intervention group
Group type: COMPARATOR
Intervention: TB-NDM (No diabetes with pulmonary tuberculosis)
Number of subjects: 0
Study 25363606 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily for 4 weeks
Number of subjects: 254
Study 25363606 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg added to tamsulosin after 4 weeks for patients with residual symptoms
Number of subjects: 254
Study 25363606 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for solifenacin add-on therapy
Number of subjects: 254
Study 25363997 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) of warfarin, aspirin, and clopidogrel
Number of subjects: 401
Study 25363997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) of warfarin and single antiplatelet agent (aspirin or clopidogrel)
Number of subjects: 401
Study 25363997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy (DAPT) of aspirin and clopidogrel
Number of subjects: 401
Study 25364884 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir plus ledipasvir for 12 weeks
Number of subjects: 14
Study 25366641 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cerebral infarction (DCI)
Number of subjects: 120